FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

This study is testing talazoparib (a PARP inhibitor drug) in women with advanced or metastatic breast cancer who have signs of a specific DNA repair defect, identified by a special laboratory test called the RECAP test — not limited to those with known BRCA gene mutations. **You may be eligible if...** - You have locally advanced or metastatic breast cancer with no curative treatment options - Your cancer has progressed in the last 4 months - Your tumor is either triple-negative, high-grade ER-positive/HER2-negative, or has a confirmed DNA repair defect (HRD) on the RECAP test or a known BRCA1/2 mutation - You are able to undergo a biopsy of an accessible tumor site **You may NOT be eligible if...** - You have brain metastases that are not stable - You have had prior treatment with a PARP inhibitor - Your general health is too poor to tolerate treatment (WHO performance status > 2) Talk to your doctor to see if this trial is right for you.